Gabelli & Co Investment Advisers’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-65,689	Closed	-$657K	–	515
2021 Q2	$657K	Buy	65,689 +7,900	+14%	+$79.1K	0.08%	165
2021 Q1	$581K	Buy	+57,789	New	+$578K	0.07%	178

Other funds holding EBACU

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return

Gabelli & Co Investment Advisers's EBACU Position: Q3 2021 in Review

Gabelli & Co Investment Advisers sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2021, closing a stake of 65,689 shares — an estimated $657K sold.

Gabelli & Co Investment Advisers first reported a position in EBACU in Q1 2021 and held it in 2 quarters. The position peaked at $657K in Q2 2021. 30 funds tracked by Wall St. Rank hold EBACU as of Q3 2021.

Gabelli & Co Investment Advisers reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2021 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 65,689 European Biotech Acquisition Corp. Units shares in Q3 2021, an estimated $657K.
Gabelli & Co Investment Advisers first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 2 quarters.
Gabelli & Co Investment Advisers's European Biotech Acquisition Corp. Units position peaked at $657K in Q2 2021.
30 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2021.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.